Pretargeted radioimmunoimaging with a biotinylated D-D construct and Tc-DTPA-biotin: strategies for early diagnosis of small cell lung cancer

Abstract

Objective Pro-gastrin releasing peptide (ProGRP) plays an oncogenic role in small cell lung cancer (SCLC). The anti-ProGRP (31-98) monoclonal antibody D-D 3 can selectively accumulate in SCLC xenografts in nude mice. This study evaluated the effectiveness of a new pretargeting procedure for the early diagnosis of SCLC. Methods D-D 3 was radiolabeled with technetium-99m ( 99m Tc) using a three-step pretargeting method. Mice with SCLC xenografts were treated with different labeling regimens, and the biodistribution and radioimmunoimaging were explored. The percentage injected dose per gram (%ID/g) in various organs, tumor/non-tumor (T/NT) ratio, and tumor/background (T/B) ratio were also calculated. Results In vivo distribution experiments revealed that 99m Tc-DTPA-biotin was metabolized in the liver and kidney, with rapid elimination in the blood. The T/B ratio was highest in mice treated with biotinylated antibody D-D 3 + avidin + 99m Tc-DTPA-biotin. Single-photon emission computerized tomography imaging further confirmed that the T/B ratio was highest in this group at all time points. Conclusions In contrast to directly labeled D-D 3 , pretargeting technology displayed specific enhancement and signal amplification in tumors, which could increase the target tumor uptake of 99m Tc and provide a new approach for the early diagnosis of SCLC.